StockNews.com began coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note released on Thursday. The firm issued a sell rating on the biotechnology company's stock.
Separately, BTIG Research cut OncoSec Medical from a buy rating to a neutral rating in a research report on Monday, November 14th.
Get OncoSec Medical alerts:OncoSec Medical Trading Down 1.7 %
Shares of OncoSec Medical stock opened at $1.71 on Thursday. The business's fifty day simple moving average is $7.71 and its 200 day simple moving average is $12.79. The firm has a market capitalization of $5.08 million, a P/E ratio of -0.08 and a beta of 1.48. OncoSec Medical has a 12 month low of $1.50 and a 12 month high of $31.90.
Institutional Investors Weigh In On OncoSec Medical
An institutional investor recently raised its position in OncoSec Medical stock. Renaissance Technologies LLC boosted its position in OncoSec Medical Incorporated (NASDAQ:ONCS – Get Rating) by 48.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 72,898 shares of the biotechnology company's stock after acquiring an additional 23,900 shares during the period. Renaissance Technologies LLC owned 0.19% of OncoSec Medical worth $54,000 as of its most recent SEC filing. 13.22% of the stock is owned by institutional investors.OncoSec Medical Company Profile
(Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
Recommended Stories
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Is AMC Entertainment Stock Worth Taking Down Here?
- Is it Time to Take a Bite into Domino's Pizza?
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.